Overview

ABY-029 Glioma Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Phase:
PHASE1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
Dartmouth College
National Cancer Institute (NCI)
Treatments:
ABY-029